Evidence map›Paper›PMID 26747781›Full record

ReviewAmerican journal of physiology. Lung cellular and molecular physiology2016

The role of hyaluronan in the pathobiology and treatment of respiratory disease.

Stavros Garantziotis, Martin Brezina, Paolo Castelnuovo, Lorenzo Drago

Open access · greenAbstract readReview
In one paragraph

Review in American journal of physiology. Lung cellular and molecular physiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 100 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Hyaluronan Is a Promising Host-directed Therapy for Viral Pneumonia.American journal of respiratory cell and molecular biology · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Hyaluronan Directs Alveolar Type II Cell Response to Acute Ozone Exposure in Mice.American journal of respiratory cell and molecular biology · 2025
    Article
  13. Article
  14. Review
  15. Identification and validation of a threshold for early posttransplant bronchoalveolar fluid hyaluronan that distinguishes lung recipients at risk for chronic lung allograft dysfunction.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 3 countries.

Stavros GarantziotisClinical Research Program, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina; garantziotis@niehs.nih.gov.
Martin BrezinaClinic of Pediatric Pneumology and Phthisiology, University Hospital Bratislava, Bratislava, Slovakia;
Paolo CastelnuovoDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Insubria, Ospedale di Circolo, Fondazione Macchi, Varese, Italy; and.
Lorenzo DragoLaboratory of Clinical Chemistry and Microbiology, IRCCS Galeazzi Orthopaedic Institute, Department of Biomedical Sciences for Health, University of Milan, Milan, Italy.
Istituto Ortopedico Galeazzi · ITNational Institute of Environmental Health Sciences · USOspedale di Circolo e Fondazione Macchi · ITUniversity Hospital Bratislava · SK

Funding

The Role of Hyaluronan And Inter-Alpha-Trypsin Inhibitor in Tissue InjuryZIAES102605 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI GARANTZIOTIS, STAVROS · 2009 to 2025
$22.6M
6 · The paper itself

Abstract

Hyaluronan, a ubiquitous naturally occurring glycosaminoglycan, is a major component of the extracellular matrix, where it participates in biological processes that include water homeostasis, cell-matrix signaling, tissue healing, inflammation, angiogenesis, and cell proliferation and migration. There are emerging data that hyaluronan and its degradation products have an important role in the pathobiology of the respiratory tract. We review the role of hyaluronan in respiratory diseases and present evidence from published literature and from clinical practice supporting hyaluronan as a novel treatment for respiratory diseases. Preliminary data show that aerosolized exogenous hyaluronan has beneficial activity against airway inflammation, protects against bronchial hyperreactivity and remodeling, and disrupts the biofilm associated with chronic infection. This suggests a role in airway diseases with a predominant inflammatory component such as rhinosinusitis, asthma, chronic obstructive pulmonary disease, cystic fibrosis, and primary ciliary dyskinesia. The potential for hyaluronan to complement conventional therapy will become clearer when data are available from controlled trials in larger patient populations.

Indexed as

AnimalsAnti-Inflammatory AgentsHumansHyaluronic AcidLungRespiratory Tract DiseasesSignal TransductionAnti-Inflammatory AgentsHyaluronic Acidasthmabacterial biofilmchronic obstructive pulmonary diseasecystic fibrosishyaluronaninflammationrespiratory tract diseases

Identifiers

PMID26747781
PMCPMC4867348
OpenAlexW2267892322

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.